Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human fibrinogen in acquired hypofibrinogenemia due to chronic liver disease
CTR20260024Phase 3Active
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Fibrinogen human in Acquired fibrinogenopenia, chronic liver disease (CLD), sponsored by Chengdu Rongsheng Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
Fibrinogen human
03
Conditions
Acquired fibrinogenopeniachronic liver disease (CLD)
Beyond the preview
Go deeper on CTR20260024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260024.